ESPAC-4: A Multicenter, International, Randomized Controlled Phase III Trial of Adjuvant Combination Chemotherapy of Gemcitabine (GEM) and Capecitabine (CAP), Versus Monotherapy Gemcitabine in Patients With Resected Pancreatic Ductal Adenocarcinoma

被引：0

作者：

Neoptolemos, J. P. ^{[1
]}

Palmer, D. ^{[1
]}

Ghaneh, P. ^{[1
]}

Valle, J. ^{[2
,3
]}

Cunningham, D. ^{[4
]}

Wadsley, J. ^{[5
]}

Meyer, T. ^{[6
]}

Anthoney, A. ^{[7
]}

Glimelius, B. ^{[8
]}

Falk, S. ^{[9
]}

Lind, P. ^{[10
]}

Izbicki, J. ^{[11
]}

Middleton, G. ^{[12
]}

Ross, P. ^{[13
]}

Wasan, H. ^{[14
]}

McDonald, A. ^{[15
]}

Crosby, T. ^{[16
]}

Psarelli, E. ^{[1
]}

Hammel, P. ^{[17
]}

Buechler, M. W. ^{[18
]}

机构：

[1] Univ Liverpool, Liverpool, Merseyside, England

[2] Univ Manchester, Manchester, Lancs, England

[3] Christie, Manchester, Lancs, England

[4] Royal Marsden Hosp, London, England

[5] Weston Pk Hosp, Sheffield, S Yorkshire, England

[6] Royal Free Hosp, London, England

[7] St James Univ Hosp, Leeds, W Yorkshire, England

[8] Uppsala Univ, Uppsala, Sweden

[9] Bristol Haematol & Oncol Ctr, Bristol, Avon, England

[10] Karolinska Univ Hosp, Stockholm, Sweden

[11] Univ Hamburg, Med Inst UKE, Hamburg, Germany

[12] Royal Surrey Cty Hosp, Guildford, Surrey, England

[13] Guys Hosp, London, England

[14] Hammersmith Hosp, London, England

[15] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[16] Velindre Hosp, Cardiff, S Glam, Wales

[17] Hop Beaujon, Clichy, France

[18] Heidelberg Univ, Heidelberg, Germany

来源：

PANCREAS | 2016年 / 45卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：1529 / 1529

页数：1

共 50 条

[41] Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses
Tempero, M. A.
Reni, M.
Riess, H.
O'Reilly, E. M.
Krishnamurthi, S.
Osterlund, P.
Ales-Diaz, I. C.
Milella, M.
Siena, S.
Tabernero, J.
Van Cutsem, E.
Philip, P. A.
Goldstein, D.
Berlin, J. D.
Li, M.
Ferrara, S.
Le Bruchec, Y.
McGovern, D.
Biankin, A.
ANNALS OF ONCOLOGY, 2019, 30
[42] A multicenter randomized phase II trial on Kanglaite Injection (KLT) plus gemcitabine hydrochloride (GEM) versus GEM in patients with local advanced and metastatic pancreatic cancer
Sun, Y.
Li, Y.
Qin, S.
Ma, D.
Jiao, S. C.
Yu, S. Y.
Li, J.
Liu, D.
Song, D.
Li, D.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[43] A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer
Pallis, A. G.
Boukovinas, I.
Ardavanis, A.
Varthalitis, I.
Malamos, N.
Georgoulias, V.
Mavroudis, D.
ANNALS OF ONCOLOGY, 2012, 23 (05) : 1164 - 1169
[44] A randomized, multi-center phase III trial of adjuvant chemotherapy with gemcitabine and capecitabine (GemCap) compared to capecitabine (Cap) alone in curatively resected biliary tract cancer (BilGemCap Study): KCSG HB20-14.
Park, Joon Oh
Park, Joon Seong
Lee, Choong-kun
Chon, Hong Jae
Choi, Sae Byeol
Hwang, Dae Wook
Oh, Do-Youn
Lee, Myung Ah
Jang, Jin-Young
Ryoo, Baek-Yeol
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS633 - TPS633
[45] A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC)
Theile, Susann
Johansen, Julia Sidenius
Nielsen, Dorte Lisbet
Jensen, Benny Vittrup
Hansen, Carsten Palnaes
Hasselby, Jane Preuss
Eiriksson, Sverrir Vidalin
Chen, Inna Markovna
PHARMACEUTICS, 2022, 14 (03)
[46] Randomized, cross-over phase III study of gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer - a multicenter trial of the "Arbeitsgemeinschaft Internistische Onkologie" (AIO)
Boeck, S.
Vehling-Kaiser, U.
Waldschmidt, D.
Kettner, E.
Maerten, A.
Winkelmann, C.
Klein, S.
Kojouharoff, G.
Jung, A.
Heinemann, V
ONKOLOGIE, 2010, 33 : 25 - 25
[47] Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial
Cognetti, F.
Ruggeri, E. M.
Felici, A.
Gallucci, M.
Muto, G.
Pollera, C. F.
Massidda, B.
Rubagotti, A.
Giannarelli, D.
Boccardo, F.
ANNALS OF ONCOLOGY, 2012, 23 (03) : 695 - 700
[48] A randomized phase II study of gemcitabine (GEM) plus S-1 combination chemotherapy versus GEM monotherapy in patients (pts) with advanced biliary tract cancer (BTC)
Sasaki, T.
Isayama, H.
Ito, Y.
Yasuda, I.
Toda, N.
Hanada, K.
Matsubara, S.
Maoguchi, H.
Yashlma, Y.
Kamada, H.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
[49] APACT: a Phase III Trial of nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) vs Gem Alone as Adjuvant Therapy for Patients (pts) with Resected Pancreatic Cancer (PC)
Tempero, M. A.
Cardin, D.
Biankin, A.
Goldstein, D.
Moore, M.
O'Reilly, E. M.
Philip, P.
Riess, H.
Macarulla, T.
Yung, L.
Wei, X.
Lu, B.
PANCREAS, 2014, 43 (08) : 1416 - 1416
[50] A randomized phase II clinical trial of gemcitabine, oxaliplatin, erlotinib combination chemotherapy versus gemcitabine and erlotinib in previously untreated patients with locally advanced or metastatic pancreatic cancer.
Lim, Sung Hee
Yun, Jina
Lee, Min-Young
Kim, Han Jo
Kim, Kyoung Ha
Kim, Se Hyung
Lee, Sang-Cheol
Bae, Sang Byung
Kim, Chan Kyu
Lee, Namsu
Lee, Kyu Taek
Park, Sung Kyu
Hong, Dae Sik
Choi, Hyun Jong
Moon, Jong Ho
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)

← 1 2 3 4 5 →